Therapeutic delivery of αvβ1 inhibitor, compound 8 (c8) inhibits αvβ1 integrin‐mediated TGF‐β activation, attenuating bleomycin‐induced pulmonary fibrosis and carbon tetrachloride‐induced liver fibrosis.161. This evidence concerns the gene TGFB1 and Hepatic fibrosis.